“Over the next three years… on the path to cross this milestone (with a hefty profitable bottom line). Our ambition is to establish the standard of care in brain health, both psychiatry and neurology across India and expand globally,” Lakshay Sahni, co-founder and CTO at Marbles Health, told Business Standard.
Around five-and-a-half months ago, Marbles Health introduced EASE, a device used by clinics and hospitals at ₹2.5 lakh and tested in more than four large independent clinical trials. The technology integrates neuromodulation, brain monitoring, and cognitive training to support recovery from neuropsychiatric conditions, including depression, anxiety, ADHD and others.
Sahni added that ongoing research suggests the device may also support patients with coordination issues, stroke recovery, and neurorehabilitation.
However, he cautioned that the device is not suitable for all users. “Patients with metal implants, a history of seizures, or skin allergies at the contact areas should avoid using it,” he noted.
The health-tech startup is preparing to raise nearly $5 million (₹45 crore) in the coming year to strengthen its EASE platform and introduce fresh offerings, supported by investors such as Capital 2B, Temasek, Whiteboard Capital, Novartis, along with government grants.
Marbles Health allocates about 35–45 per cent of its funds to research and development (R&D). Among its upcoming offerings is an at-home mental health care device, expected to be priced around ₹25,000. The company is also developing a specialised programme to support mothers in managing brain health during the pre- and post-pregnancy phases through EASE. The device is currently under regulatory approvals.
“We are well-capitalised and are channeling resources strategically into three areas such as expanding adoption in India, accelerating international regulatory approvals, and advancing product innovation. Our investment will be aligned with scaling responsibly while maintaining medical leadership,” he said.
Marbles Health is placing artificial intelligence (AI) at the core of its technology road map. On the clinical front, the company is using AI to personalise neuromodulation protocols, integrate EEG signals, and monitor cognitive and emotional outcomes. For patients, AI powers more adaptive, measurement-based care journeys. Going ahead, the company envisions AI enabling predictive models of treatment response, paving the way for individualised brain healthcare.
Marbles Health has established a presence across 15 locations, including Delhi-NCR, Hyderabad, Mumbai and Bengaluru, with upcoming expansions in Kolkata and Chennai. The company has set focus on Tier-I and Tier-II cities to strengthen the domestic footprint. On the other hand, it has signed an MoU with the National Health Services (NHS), marking a significant step toward global collaboration.
As part of its global vision, Marbles Health plans to expand into the US, Europe, and Africa. “Neuropsychiatric conditions affect one in seven households worldwide. Over the next five years, we aim to bring solutions directly to this demography,” the company stated.
The startup also plans to partner with insurance companies within the next year to make mental healthcare more seamless and affordable. “The cost of treatment for chronic conditions and psychiatric consultations remains very high in India. While some insurers do cover mental health, the majority still focus primarily on cardiology and surgical care,” the company said.
Marbles Health has tied-up with KMC Manipal, NIMHANS, CIP Ranchi, Mansa Clinic in Pune, De Sousa Foundation in Mumbai, Fortis Shalimar Bagh and CCAW in Delhi, among others. Moreover, the company’s advisory board includes professors from UC Berkeley, AIIMS Delhi, and Harvard.
 "Marbles Health")